1 January 2026 - The January 2026 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The January issue of the Schedule includes has a few new/revised listings of note:

• Dapsone (Dapsomed) - new strength
• Odevixibat sesquihydrate (Bylvay) - new medicine
• Teriparatide (Ritosa) - new biosimilar medicine
• Ublituximab (Briumvi) - new medicine

Read summary of PBS changes